Cencora Sees Specialty Growth Continue While GLP-1 Mix Weighs on Margins
Cencora beats third-quarter earnings and revenue estimates, raised fiscal 2026 EPS guidance and maintains its annual sales forecast.
Cencora did better than expected this quarter and thinks it will make more money next year, which is good. But a new type of medicine (GLP-1 drugs) is making their profits smaller, so watch whether that trend keeps happening or stops.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.